Biotech - Drug Development
Biotechnology companies developing novel therapeutics across disease areas (excluding oncology-focused)
Rare Disease Therapeutics152
Neuroscience & CNS90
Immunology & Autoimmune80
Metabolic & Cardiometabolic42
Infectious Disease & Vaccines51
Clinical-Stage Platforms148
| Ticker | Company | Sub-Theme | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co. | Metabolic & Cardiometabolic | $0.8t | $871.50 | -1.4% | 2.7M |
 JNJ | Johnson & Johnson | Immunology & Autoimmune | $0.6t | $225.21 | -1.0% | 7.9M |
 ABBV | ABBVIE INC. | Immunology & Autoimmune | $377.0b | $198.28 | -0.2% | 7.5M |
 AZN | AstraZeneca PLC | Metabolic & Cardiometabolic | $300.7b | $188.23 | -0.8% | 2.1M |
 MRK | Merck & Co., Inc. | Infectious Disease & Vaccines | $292.0b | $110.34 | -1.4% | 9.2M |
 AMGN | Amgen Inc | Rare Disease TherapeuticsImmunology & Autoimmune | $188.1b | $340.17 | -1.3% | 2.6M |
 TMO | Thermo Fisher Scientific, Inc. | Clinical-Stage Platforms | $178.3b | $467.88 | -0.4% | 2.3M |
 GILD | Gilead Sciences Inc | Infectious Disease & Vaccines | $169.2b | $127.72 | -2.1% | 8.2M |
 PFE | Pfizer Inc. | Infectious Disease & Vaccines | $158.0b | $26.85 | -0.6% | 34.8M |
 BMY | Bristol-Myers Squibb Co. | Immunology & Autoimmune | $122.0b | $57.89 | -1.4% | 10.7M |
 VRTX | Vertex Pharmaceuticals Inc | Rare Disease Therapeutics | $112.6b | $425.98 | -1.0% | 966.9K |
 REGN | Regeneron Pharmaceuticals Inc | Immunology & Autoimmune | $79.2b | $744.61 | -0.9% | 603.2K |
 ALNY | Alnylam Pharmaceuticals, Inc. | Rare Disease Therapeutics | $41.9b | $308.65 | +1.0% | 1.1M |
 INSM | Insmed, Inc. | Rare Disease Therapeutics | $33.0b | $136.00 | +0.6% | 1.1M |
 A | Agilent Technologies Inc. | Clinical-Stage Platforms | $31.7b | $115.62 | +0.1% | 1.5M |
 WAT | Waters Corp | Clinical-Stage Platforms | $28.8b | $304.93 | -1.6% | 1.2M |
 IQV | IQVIA Holdings Inc. | Clinical-Stage Platforms | $27.9b | $163.84 | +1.0% | 982.4K |
 BIIB | Biogen Inc. Common Stock | Neuroscience & CNS | $27.5b | $180.63 | -2.0% | 1.1M |
 UTHR | United Therapeutics Corp | Rare Disease Therapeutics | $25.8b | $567.16 | 0.0% | 242.4K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Clinical-Stage Platforms | $19.9b | $49.65 | +0.5% | 4.1M |
 MRNA | Moderna, Inc. Common Stock | Infectious Disease & Vaccines | $19.1b | $48.68 | -4.0% | 6.1M |
 ROIV | Roivant Sciences Ltd. Common Shares | Immunology & Autoimmune | $18.9b | $27.85 | +1.6% | 5.0M |
 INCY | Incyte Genomics Inc | Rare Disease Therapeutics | $18.0b | $95.70 | +1.1% | 2.1M |
 WST | West Pharmaceutical Services, Inc. | Clinical-Stage Platforms | $17.7b | $302.20 | -1.3% | 1.1M |
 BBIO | BridgeBio Pharma, Inc. Common Stock | Rare Disease Therapeutics | $13.4b | $74.49 | +1.7% | 3.0M |
 SMMT | Summit Therapeutics Inc. Common Stock | Infectious Disease & Vaccines | $13.2b | $22.13 | +0.2% | 3.7M |
 MEDP | Medpace Holdings, Inc. Common Stock | Clinical-Stage Platforms | $13.1b | $421.61 | +2.7% | 618.2K |
 NBIX | Neurocrine Biosciences Inc | Neuroscience & CNS | $12.9b | $128.04 | +0.3% | 1.5M |
 IONS | Ionis Pharmaceuticals, Inc. Common Stock | Rare Disease Therapeutics | $12.0b | $72.28 | -1.3% | 2.3M |
 MDGL | Madrigal Pharmaceuticals, Inc. Common Stock | Metabolic & Cardiometabolic | $11.6b | $520.05 | +1.5% | 216.0K |
 RGC | Regencell Bioscience Holdings Limited Ordinary Shares | Neuroscience & CNS | $11.5b | $29.23 | +6.3% | 161.7K |
 JAZZ | Jazz Pharmaceuticals, Inc. | Neuroscience & CNS | $11.3b | $201.26 | +2.4% | 1.3M |
 BMRN | BioMarin Pharmaceuticals Inc | Rare Disease Therapeutics | $10.5b | $53.81 | +1.2% | 1.5M |
 RVTY | Revvity, Inc. | Clinical-Stage Platforms | $9.5b | $86.80 | +0.0% | 1.0M |
 AXSM | Axsome Therapeutics, Inc | Neuroscience & CNS | $8.2b | $187.26 | +0.7% | 919.9K |
 TECH | Bio-Techne Corp. | Clinical-Stage Platforms | $8.1b | $55.12 | +1.7% | 1.5M |
 QGEN | QIAGEN N.V. | Clinical-Stage Platforms | $8.1b | $36.60 | -4.7% | 1.5M |
 BIO.B | Bio-Rad Laboratories, Inc. Class B | Clinical-Stage Platforms | $8.1b | $292.34 | -2.4% | 76 |
 ARWR | Arrowhead Research Corporation | Rare Disease Therapeutics | $8.1b | $73.56 | -0.5% | 1.4M |
 ICLR | Icon Plc | Clinical-Stage Platforms | $8.0b | $103.14 | +1.0% | 3.4M |
 PCVX | Vaxcyte, Inc. Common Stock | Infectious Disease & Vaccines | $7.9b | $59.77 | +0.5% | 1.0M |
 CRL | Charles River Laboratories International, Inc. | Clinical-Stage Platforms | $7.9b | $171.23 | +0.8% | 750.6K |
 CYTK | Cytokinetics Inc. | Rare Disease TherapeuticsNeuroscience & CNS | $7.8b | $61.63 | -5.7% | 2.3M |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | Neuroscience & CNS | $7.7b | $331.16 | -4.0% | 358.6K |
 HALO | Halozyme Therapeutics, Inc. | Clinical-Stage Platforms | $7.4b | $64.49 | -1.3% | 1.3M |
 KRYS | Krystal Biotech, Inc. Common Stock | Rare Disease Therapeutics | $7.2b | $272.65 | +0.0% | 242.4K |
 IBRX | ImmunityBio, Inc. Common Stock | Immunology & Autoimmune | $6.8b | $7.30 | -1.9% | 11.1M |
 KYMR | Kymera Therapeutics, Inc. Common Stock | Clinical-Stage Platforms | $6.5b | $86.68 | +2.1% | 513.6K |
 PTGX | Protagonist Therapeutics, Inc | Metabolic & CardiometabolicImmunology & Autoimmune | $6.4b | $98.43 | -1.6% | 994.7K |
 RGEN | Repligen Corp | Clinical-Stage Platforms | $6.3b | $118.35 | +0.6% | 907.8K |